Evaluating Incadronate for Breast Cancer with Bone Metastases
Official title: Real-world Study of Incadronate in Breast Cancer Patients With Metastatic Bone Disease: clinIcal Efficacy and Safety
Run by Fudan University · NCT06392217 · Data updated 2026-11-12
This study is testing if incadronate can help people with breast cancer that has spread to their bones feel better and stay safe while using the treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | March 12, 2024 |
| Main results expected | July 1, 2027 |
| Study ends | January 1, 2028 |
| Registry record updated | November 2, 2026 |
| Trial ID | NCT06392217 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with histologically confirmed breast cancer and imaging-confirmed bone metastases.
✕Probably not a fit
Patients who are pregnant or lactating, or those with serious concurrent diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the efficacy and safety of incadronate in patients suffering from breast cancer with bone metastases. It involves real-world data collection from participants who meet specific eligibility criteria, including confirmed breast cancer and bone metastases. The study will monitor the outcomes of treatment with incadronate, focusing on both its effectiveness and any potential side effects experienced by the patients.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for breast cancer patients with bone metastases, potentially improving their quality of life and treatment outcomes.
How similar studies have gone: While this study focuses on a specific treatment approach, similar studies evaluating bisphosphonates for bone metastases in breast cancer have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female aged 18 years or above; 2. Can understand the purpose of clinical trials and the benefits and risks, voluntarily participate in and sign the informed consent 3. The physical status score of the Eastern Cooperative Oncology Group (ECOG) was ≤3; 4. Histologically or cytologically confirmed breast cancer; 5. Imaging or histocytology confirmed bone metastases; 6. There were indications of useing Incadronate and no contraindications in the use of Incadronate; 7. New York Heart Association(NYHA)cardiac function grade ≤II, No serious heart disease; 8. All women of childbearing age, fertile men or their spouses did not plan to have children or donate sperm throughout the trial period until 6 months after the last dose, or voluntarily took effective contraceptive measures. Exclusion Criteria: 1. Pregnant or lactating women; 2. Patients with acute and chronic infections, or with other serious diseases at the same time, were judged not suitable for this study; 3. Other malignant tumors within 5 years (except the following cases: cured skin basal cell carcinoma, cervical carcinoma in situ, thyroid papillary carcinoma; A second primary cancer that has been eradicated and has not recurred within five years; Investigators have identified the primary tumor source of the metastases); 4. Mental illness or mental disorder, poor compliance can not cooperate with and describe treatment response; 5. There are serious organic diseases or major organ failure, such as decompensated heart, lung, liver, kidney failure, which can not tolerate treatment; 6. Patients with bleeding tendency; 7. The researcher believes that the patient has other conditions that are not suitable for participating in this study.
Where it's running
-
Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Jian Zhang
- Email: syner2000@163.com
- Phone: +8664175590
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using targeted radiation therapy for breast cancer bone metastases
This study is testing a new type of targeted radiation therapy for people with breast cancer that has spread to their bones to see if it can help them feel better and improve their treatment outcomes.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.